Metronomic Chemotherapy in Ovarian Cancer: Current Scenario and AI-Integrated Future Strategies [0.03%]
卵巢癌的节律化疗：当前情况及AI整合未来策略
Ravi Chauhan,Suraja Kumar Das,Lakshay Malhotra et al.
Ravi Chauhan et al.
Background: Ovarian cancer (OC) is a globally prevalent malignancy associated with a high mortality rate and marked biological heterogeneity, with most cases arising from epithelial cells and presenting as serous, endomet...
Breast Cancer Presentation, Treatment Patterns, and Progression-Free Survival at a Tertiary Oncology Centre in Bangladesh: A Retrospective Study [0.03%]
孟加拉国三级肿瘤治疗中心的乳腺癌患者特征、治疗模式和无进展生存期：一项回顾性研究
Qamruzzaman Chowdhury,Md Arifur Rahman,Ferdous Ara Begum et al.
Qamruzzaman Chowdhury et al.
Background: Breast cancer remains a major cause of cancer-related morbidity among women worldwide, with persistent disparities in diagnosis, treatment access, and outcomes across low- and middle-income settings. Instituti...
Observational Study
Cancer reports (Hoboken, N.J.). 2026 Jul;9(7):e70623. DOI:10.1002/cnr2.70623 2026
Nw-Hydroxy L-Arginine (NOHA): A Promising Biomarker of Response to Neoadjuvant Therapy in the Management of Triple Negative Breast Cancer [0.03%]
Nw-羟基L-精氨酸(NOHA)作为三阴性乳腺癌新辅助治疗疗效生物标志物的潜力研究
Srinidi Mohan,Douglas W Van Pelt,Jamie G Saunders et al.
Srinidi Mohan et al.
Background: Oncologists lack effective point-of-care biomarkers to rapidly adapt curative-intent triple negative breast cancer (TNBC) neoadjuvant therapy (NT). Previous work reveals that Nw-hydroxy-L-Arginine (NOHA) is an...
Investigating the Role of Anti-Leukemia Inhibitory Factor Antibody on Cytokine Profile in a Mouse Model of Breast Cancer [0.03%]
抗白血病抑制因子抗体对乳腺癌小鼠模型细胞因子谱的作用研究
Seyed Mohammad Seifati,Hossein Hadinedoushan,Hossein Ansariniya et al.
Seyed Mohammad Seifati et al.
Background: Leukemia inhibitory factor (LIF), a member of the IL-6 cytokine family, is increasingly recognized as a tumor-promoting factor in breast cancer, where it contributes to immune suppression, tumor progression, a...
Patterns of Body Composition Changes and Their Predictors During Cancer Therapy in Newly Diagnosed Adult Oncology Patients With Varying Baseline Nutritional Status at a Tertiary Hospital in Ethiopia: A Prospective Cohort Study [0.03%]
埃塞俄比亚三级医院新诊断成人肿瘤患者癌症治疗期间体成分变化模式及其预测因素：一项前瞻性队列研究
Abebe Dukessa Dubiwak,Mulualem Tadesse,Tefera Belachew et al.
Abebe Dukessa Dubiwak et al.
Background: Cancer incidence is an emerging public health problem in low- and middle-income countries. Despite strong recommendations from the European Society for Clinical Nutrition and Metabolism expert to expand nutrit...
Advancing Cancer Cachexia Drug Development: Leveraging Biomarkers and Functional Endpoints to Optimize Trial Design [0.03%]
推进癌症恶病质药物研发：利用生物标志物和功能性终点优化试验设计
Nada O Othman,Hadir Habib,Doaa M Almeldin et al.
Nada O Othman et al.
Background: Cancer-associated cachexia is a complex, multistage metabolic disorder that markedly contributes to morbidity and mortality in patients with advanced cancer, yet effective pharmacological interventions are lac...
Salvage Therapy With Inotuzumab Ozogamicin in Relapsed/Refractory B-ALL After CAR-T Therapy and HSCT: A Case Series [0.03%]
靶向CD19 CAR-T和HSCT后复发难治B细胞急性淋巴细胞白血病患者使用Inotuzumab Ozogamicin救治的病例报告系列研究
Honghu Li,Luxin Yang,Lizhen Liu et al.
Honghu Li et al.
Background: Although inotuzumab ozogamicin (InO) has been approved as an effective agent for patients with refractory/relapsed (r/r) B-cell acute lymphoblastic leukemia (B-ALL), data in the context of post chimeric antige...
Development of a Tumor-Bearing Animal Model to Evaluate Chemotherapy Efficacy and Toxicity [0.03%]
用于评估化疗有效性和毒性的荷瘤动物模型的建立
Ifeoma J Dikeocha,Emma Bateman,Hannah R Wardill et al.
Ifeoma J Dikeocha et al.
Background: The value of cancer therapies lies in enhancing anti-tumor efficacy while minimizing toxicity. However, these aspects are rarely studied together, often due to the challenges of modelling both within the same ...
Yue Li,Longqian Wei,Guiyu Feng et al.
Yue Li et al.
Background: CCT7 is a chaperonin containing tailless complex polypeptide 1 subunit. The study focused on investigating its prognostic significance for lung adenocarcinoma (LUAD). ...
Pembrolizumab-Induced Myositis: Diagnostic and Therapeutic Challenges From Two Case Reports and a Narrative Review [0.03%]
派姆单抗致肌炎：两例报道及文献回顾中的诊断和治疗挑战
Francesca Rifaldi,Niccolò Leandro Alessio,Francesca Caspani et al.
Francesca Rifaldi et al.
Background: Pembrolizumab, an anti-PD-1 immune checkpoint inhibitor, has transformed the treatment of multiple solid tumors. However, it can rarely cause immune-related myositis, which may involve limb, bulbar, and respir...